全文获取类型
收费全文 | 28067篇 |
免费 | 1527篇 |
国内免费 | 259篇 |
专业分类
耳鼻咽喉 | 246篇 |
儿科学 | 547篇 |
妇产科学 | 579篇 |
基础医学 | 2835篇 |
口腔科学 | 665篇 |
临床医学 | 1988篇 |
内科学 | 8082篇 |
皮肤病学 | 352篇 |
神经病学 | 2405篇 |
特种医学 | 1067篇 |
外科学 | 5192篇 |
综合类 | 54篇 |
一般理论 | 5篇 |
预防医学 | 1106篇 |
眼科学 | 574篇 |
药学 | 1634篇 |
中国医学 | 57篇 |
肿瘤学 | 2465篇 |
出版年
2024年 | 31篇 |
2023年 | 291篇 |
2022年 | 605篇 |
2021年 | 1028篇 |
2020年 | 585篇 |
2019年 | 837篇 |
2018年 | 1000篇 |
2017年 | 727篇 |
2016年 | 880篇 |
2015年 | 899篇 |
2014年 | 1217篇 |
2013年 | 1502篇 |
2012年 | 2284篇 |
2011年 | 2165篇 |
2010年 | 1249篇 |
2009年 | 1201篇 |
2008年 | 1874篇 |
2007年 | 1815篇 |
2006年 | 1704篇 |
2005年 | 1695篇 |
2004年 | 1591篇 |
2003年 | 1362篇 |
2002年 | 1233篇 |
2001年 | 131篇 |
2000年 | 127篇 |
1999年 | 170篇 |
1998年 | 207篇 |
1997年 | 165篇 |
1996年 | 156篇 |
1995年 | 150篇 |
1994年 | 127篇 |
1993年 | 116篇 |
1992年 | 89篇 |
1991年 | 56篇 |
1990年 | 64篇 |
1989年 | 48篇 |
1988年 | 40篇 |
1987年 | 35篇 |
1986年 | 43篇 |
1985年 | 37篇 |
1984年 | 34篇 |
1983年 | 32篇 |
1982年 | 49篇 |
1981年 | 29篇 |
1980年 | 27篇 |
1979年 | 17篇 |
1978年 | 12篇 |
1976年 | 11篇 |
1975年 | 8篇 |
1974年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Stefania Momi Jessica Canino Mauro Vismara Luca Galgano Emanuela Falcinelli Giuseppe Guglielmini Giulia Ciarrocca Taranta Gianni Francesco Guidetti Paolo Gresele Mauro Torti Ilaria Canobbio 《Haematologica》2022,107(6):1374
Deep vein thrombosis results from the cooperative action of leukocytes, platelets, and endothelial cells. The proline-rich tyrosine kinase Pyk2 regulates platelet activation and supports arterial thrombosis. In this study, we combined pharmacological and genetic approaches to unravel the role of Pyk2 in venous thrombosis. We found that mice lacking Pyk2 almost completely failed to develop deep venous thrombi upon partial ligation of the inferior vena cava. Pyk2-deficient platelets displayed impaired exposure of phosphatidylserine and tissue factor expression by endothelial cells and monocytes was completely prevented by inhibition of Pyk2. In human umbilical vein endothelial cells (HUVEC), inhibition of Pyk2 hampered IL-1β-induced expression of VCAM and P-selectin, and von Willebrand factor release. Pyk2-deficient platelets showed defective adhesion on von Willebrand factor and reduced ability to bind activated HUVEC under flow. Moreover, inhibition of Pyk2 in HUVEC strongly reduced platelet adhesion. Similarly, Pyk2-deficient neutrophils were unable to efficiently roll and adhere to immobilized endothelial cells under venous flow conditions. Moreover, platelets and neutrophils from Pyk2-knockout mice showed defective ability to form heterogeneous aggregates upon stimulation, while platelet monocyte interaction occurred normally. Consequently, platelet neutrophil aggregates, abundant in blood of wild-type mice upon inferior vena cava ligation, were virtually undetectable in Pyk2-knockout mice. Finally, we found that expression of Pyk2 was required for NETosis induced by activated platelets. Altogether our results demonstrate a critical role of Pyk2 in the regulation of the coordinated thromboinflammatory responses of endothelial cells, leukocytes and platelets leading to venous thrombosis. Pyk2 may represent a novel promising target in the treatment of deep vein thrombosis. 相似文献
92.
Michele Brun Elisa Sogne Andrea Falqui Federico Scaglione Paola Rizzi Francesco Delogu Giorgio Pia 《Materials》2022,15(10)
Nanoporous Au has been subjected to serial block face-scanning electron microscopy (SBF-SEM) 3D-characterisation. Corresponding sections have been digitalized and used to evaluate the associated mechanical properties. Our investigation demonstrates that the sample is homogeneous and isotropic. The effective Young’s modulus estimated by an analytical multiscale approach agrees remarkably well with the values stated in the literature. 相似文献
93.
Valentina Baro Giulia Cerretti Michela Todoverto Alessandro Della Puppa Franco Chioffi Francesco Volpin Francesco Causin Fabio Busato Pasquale Fiduccia Andrea Landi Domenico dAvella Vittorina Zagonel Luca Denaro Giuseppe Lombardi 《Current oncology (Toronto, Ont.)》2022,29(5):3472
Simple SummaryGlioblastoma is an aggressive brain tumor with a dismal prognosis. In a minority of cases, it presents with multiple lesions already at the time of diagnosis, affecting patients’ survival and treatment. Our retrospective study aims to increase the current understanding and define a treatment for this sub-entity, to improve patient survival. Chemoradiotherapy is a also safe and efficacy treatment in patients with multiple lesions. Survival advantages from extensive resection remain unclear.AbstractGlioblastomas with multiple foci at presentation (mGBMs) account for 2–35% of all GBMs. mGBMs have limited existing data and no standardized treatment. This study aims to determine their incidence, demographic and clinical features, outcome, and prognostic factors in terms of overall survival. We performed a monocentric retrospective study, reviewing patients treated at the Istituto Oncologico Veneto. Inclusion criteria were: new diagnosis of GBM and presence of multiple lesions on pre-treatment MRI. ECOG PS was used to evaluate clinical condition, RANO criteria for radiological assessment, and CTCAE v5.0 for treatment-related adverse events. The incidence of newly diagnosed mGBM was 7.2% and the study population consisted of 98 patients. Median age was 63 years, M:F ratio of 1.8:1, and a surgical approach was undertaken in 73 patients (mostly partial resection). MGMT was methylated in 47.5%, and 82 patients received active oncological treatment (65.9% radiotherapy plus temozolomide (RT + TMZ)). The disease control rate with RT + TMZ was 63%. Median OS of the entire study population was 10.2 months (95% CI 6.6–13.8), and median PFS was 4.2 months (95% CI 3.2–5.2). The ECOG PS, the extent of resection, and the RT + TMZ were significant prognostic factors in the univariate analysis for OS, but only the RT + TMZ was a significant independent OS predictor in the multivariate analysis (HR = 3.1, 95% IC 1.3–7.7, p = 0.014). The incidence of mGBM is not rare. RT + TMZ is confirmed to be an independent prognostic factor for survival and a safe and effective treatment. When feasible, RT + TMZ should be considered as a possible first-line treatment. The role of the extent of resection is still unclear. 相似文献
94.
Giulia Di Carlo Nicola Mascolo Angelo Antonio Izzo Francesco Capasso Giuseppina Autore 《Phytotherapy research : PTR》1994,8(1):42-45
Intraperitoneal administration of quercetin (6.25–50 mg/kg) significantly (p<0.5-0.01) reduced intestinal transit in mice and this effect was antagonized by yohimbine and phentolamine but not by atropine or naloxone. Quercetin (12.5–50 mg/kg) reduced also (p<0.05-0.01) intraluminal accumulation of fluid and diarrhoea induced by castor oil and these effects were antagonized by yohimbine. Finally quercetin (12.5–50 mg/kg) reduced the area of gastric ulcer but not the number. It is suggested that α2-adrenergic receptors mediate the effect of quercetin on intestinal motility and secretion. 相似文献
95.
Sebastian D. Sahli Alexander Kaserer Julia Braun Maximilian Halbe Yuliya Dahlem Muriel A. Spahn Julian Rssler Bernard Krüger Francesco Maisano Donat R. Spahn Markus J. Wilhelm 《Journal of thoracic disease》2022,14(6):1960
BackgroundExtracorporeal life support (ECLS) therapy is increasingly used for cardiac and respiratory support postcardiotomy, refractory cardiogenic shock and cardiopulmonary resuscitation. This study aims to describe in-hospital mortality of patients requiring ECLS, identify independent predictors associated with mortality and analyze changes of mortality over time.MethodsThis retrospective study includes all adult ECLS cases at the University Hospital Zurich, a designated ECLS center in Switzerland, in the period 2007 to 2019.ResultsECLS therapy was required in 679 patients (median age 60 years, 27.5% female). In-hospital mortality was 55.5%. Cubic spline interpolation did not detect evidence for a change in mortality over the whole period of 13 years. In-hospital mortality significantly varied between ECLS indications: 70.7% (152/215) for postcardiotomy, 67.9% (108/159) for cardiopulmonary resuscitation, 47.0% (110/234) for refractory cardiogenic shock, and 9.9% (7/71) for lung transplantation and expansive thoracic surgery (P<0.001). Logistic regression modelling showed excellent discrimination in the receiver operating characteristic (ROC) area under the curve (AUC) of 0.89 [95% confidence interval (CI): 0.87–0.92] and identified significant mortality predictors: age, simplified acute physiology score (SAPS) II, as well as new liver failure and each allogenic blood transfusion unit given per day. ECLS after cardiopulmonary resuscitation was associated with significantly higher mortality compared to ECLS for refractory cardiogenic shock.ConclusionsIn-hospital mortality of patients treated with ECLS therapy is high. Outcomes have not changed significantly in the observed period. We identified age, SAPS II, new liver failure and each allogenic blood transfusion unit given per day as independent mortality predictors. Knowledge of predictors strongly associated with in-hospital mortality may affect future decisions about ECLS indications and the respective management to use this elaborate therapy more effectively. 相似文献
96.
Giovanni Corsetti Claudia Romano Silvia Codenotti Evasio Pasini Alessandro Fanzani Francesco S. Dioguardi 《Nutrients》2022,14(14)
Background: Excess body adipose tissue accumulation is a common and growing health problem caused by an unbalanced diet and/or junk food. Although the effects of dietary fat and glucose on lipid metabolism regulation are well known, those of essential amino acids (EAAs) have been poorly investigated. Our aim was to study the influence of a special diet containing all EAAs on retroperitoneal white adipose tissue (rpWAT) and interscapular brown adipose tissue (BAT) of mice. Methods: Two groups of male Balb/C mice were used. The first was fed with a standard diet. The second was fed with an EAAs-rich diet (EAARD). After 3 weeks, rpWAT and BAT were removed and prepared for subsequent immunohistochemical analysis. Results: EAARD, although consumed significantly less, moderately reduced body weight and BAT, but caused a massive reduction in rpWAT. Conversely, the triceps muscle increased in mass. In rpWAT, the size of adipocytes was very small, with increases in leptin, adiponectin and IL-6 immunostaining. In BAT, there was a reduction in lipid droplet size and a simultaneous increase in UCP-1 and SIRT-3. Conclusions: A diet containing a balanced mixture of free EAA may modulate body adiposity in mice, promoting increased thermogenesis. 相似文献
97.
98.
99.
Hamzeh Kayhanian Emily Goode Francesco Sclafani Joo Ern Ang Marco Gerlinger David Gonzalez de Castro Scott Shepherd Clare Peckitt Sheela Rao David Watkins Ian Chau David Cunningham Naureen Starling 《Clinical colorectal cancer》2018,17(1):e69-e76
Background
Somatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis. Patient outcome outside of clinical trials has only been reported in small series. We report real-world data on treatment and survival for BRAF-mutated (MT) patients at a single tertiary center, compared with a matched BRAF wild type (WT) control group.Patients and Methods
All colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified. BRAF-MT mCRC cases were compared with an age and sex-matched BRAF-WT control group. Clinicopathological data were collected and survival calculated using the Kaplan–Meier method and comparisons made using Cox regression.Results
Forty-three of 503 patients (8.5%) tested had BRAF-MT mCRC and were compared with 88 BRAF-WT controls. Median overall survival (mOS) was 18.2 months for BRAF-MT and 41.1 months for BRAF-WT mCRC patients (hazard ratio, 2.74; 95% confidence interval, 1.60-4.70; P < .001). Progression-free survival for BRAF-MT and WT patients, respectively, was: 8.1 months versus 9.2 months (P = .571) first-line, 5.5 months versus 8.3 months (P = .074) second-line, and 1.8 months versus 5.6 months (P = .074) third-line. Treatment using sequential fluoropyrimidine-based doublet chemotherapy was similar between both groups. Anti-epidermal growth factor receptor (EGFR) therapy was mainly given third-line with progressive disease in 90% (n = 9 of 10) of BRAF-MT patients at first restaging.Conclusion
In this case-control study, the poor mOS of BRAF-MT mCRC was associated with reduced treatment benefit beyond first-line. Sequential doublet chemotherapy remains a reasonable option in appropriately selected patients. BRAF-MT patients did not benefit from anti-EGFR therapy in this study. Recruitment to clinical trials is recommended to improve outcomes in BRAF-MT mCRC. 相似文献100.
Francesco Sesti Francesca Calonzi Velia Ruggeri Adalgisa Pietropolli Emilio Piccione 《International journal of gynaecology and obstetrics》2008,103(3):227-231